Navigation Links
Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office
Date:9/13/2007

r ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the continued availability of capital to finance our activities; our ability to continue to integrate into our business the operations of American Medical Instruments Holdings, Inc. ("AMI"); our ability to achieve the operational and other synergies and the other commercial or financial benefits expected as a result of the acquisition of AMI; and any other factors referenced in our annual information form and other filings with the applicable Canadian securities regulatory authorities or the SEC.

Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this prospectus to reflect future results, events or developments.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angi
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medical College receives $377K to study brain disease
2. Lucigen receives $750K grant to boost biofuel yields
3. Medical College receives $1.4M cancer grant
4. Wisconsin biotech firm receives $107K NIH grant
5. InvivoSciences receives NIH grant for heart technology
6. Medical College receives $11 million grant to study high blood pressure
7. Madison business receives $115,000 of new state biofuels funding
8. Superior receives funds for technical training
9. UWM receives state funding for plastics research
10. GEs Centricity EHR receives federal certification
11. WHIE receives state eHealth Initiative contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
(Date:2/26/2015)... NJ (PRWEB) February 26, 2015 On ... and its affiliated companies, Wilentz, Goldman & Spitzer, ... a trade secrets lawsuit against Genewiz Inc. in excess ... obtained and utilized GenScript’s trade secrets, and that it ... The court entered an order denying motions for judgment ...
(Date:2/26/2015)... Already well respected for accuracy, HEIDENHAIN now ... Length Gauge offerings with new variants of its successful ... HEIDENHAIN’s pencil probe-style SPECTO length gauge series now offers ... 1Vpp, 12mm stroke length variants of the SPECTO series ... variant with a weak spring, 0.4N of gauging force, ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Regis Extends cGMP Services to Oncology Market 2
... Mass., Sept. 26, 2011 Enanta Pharmaceuticals, Inc. ... its NS5A hepatitis C virus (HCV) inhibitor program, EDP-239, ... 10 Most Interesting Infectious Disease Projects to Watch." EDP-239 ... Herndon Company. NS5A, a clinically-validated target, ...
... - Clean solutions to human energy demands are essential to ... energy at our disposal, we have yet to learn how ... to University of Toronto chemistry professor Greg Scholes, the answers ... nature. "Solar fuel production often starts with the energy ...
... the development of the first laser in 1960 scientists discovered ... a different color; more specifically, it produced light of exactly ... second harmonic generation. The green laser pointers in ... but producing such a beautiful emerald beam is no easy ...
Cached Biology Technology:Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 2Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch 3Nature offers key lessons on harvesting solar power, says U of T chemistry professor 2Stanford engineers create nanoscale nonlinear light source 2Stanford engineers create nanoscale nonlinear light source 3Stanford engineers create nanoscale nonlinear light source 4
(Date:2/12/2015)... Feb. 12, 2015   MedNet Solutions , ... clinical study management systems, has recently bolstered its ... distinguishing iMedNet as the ... (CROs) and healthcare consultants.  Building on the Program,s ... referrals and numerous co-marketing opportunities), MedNet,s new and ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... The perception that antibiotic resistance is primarily the undesirable ... that is simplistic and inaccurate, according to a recent ... reasons behind the spread of resistance are much more ... and hygiene, and even the environment. The report, ...
... GAINESVILLE, Fla. A team of researchers including ... cache of plant fossils discovered in Colombia to provide ... 58 million years ago. Researchers from the Smithsonian ... the dominant plant families existing in today,s Neotropical rainforests ...
... release is available in French . ... Vice-Chancellor of Concordia University is delighted to announce the ... stands for Prevention, Evaluation, Rehabilitation, FORMation. The ... of $34,972,317 from the Federal and Provincial Governments, through ...
Cached Biology News:Misuse of antibiotics not the only cause of resistance says report 2Plant fossils give first real picture of earliest Neotropical rainforests 2Plant fossils give first real picture of earliest Neotropical rainforests 3Concordia University to build innovative centre for health research and training 2
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
...
... standard water based mounting medium for immunohistology. ... preservation of peroxidase and alkaline phosphatase stained ... and exhibits excellent optical characteristics. Crystal / ... that permits the long-term storage of antigens ...
Biology Products: